For starters, taking the company private could take more than $55 billion in debt, a tough move to finance amid slumping stocks.
What will it take for pharmaceutical companies to create a viable strep vaccine?
Azar will be replacing Tom Price, the former HHS secretary who resigned amid a private plane scandal in September.
Democracy Forward is suing for details about a former pharmaceutical lobbyist's role in drug regulation.
The maker of Botox has been accused of unethical practices—but those accusations are also raising suspicions.
Pharmacy benefit managers arose to fulfill a need created by the Medicare Modernization Act. But now these companies are contributing to escalating drug prices, the very opposite of their original purpose.
The SEC has allowed pharma CEOS to block shareholder resolutions that seek detail on price increases for major medicines.
Without laws to enforce them, the president's ideas to control drug prices will do just the opposite.
Takeda CFO James Kehoe said the company was on the hunt for hit drugs.
Pfizer seems to have taken note of others' stumbles in its efforts to break the failure streak of Alzheimer's drugs.
A board committee said its five-month investigation found broad accounting problems dating back to December 2014.
Signiﬁcant obstacles discourage pharma companies from devoting the power needed to develop a patentable drug to take the plant's place.